iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

IMDX expects to meet investors at the Sept. 10, 2026 BIG10 conference in New York, with CEO Josh Riggs and CFO Andrea James via one-on-one sessions arranged through Lake Street.

Rhea-AI Summary

Insight Molecular Diagnostics (IMDX) will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference on September 10, 2026, in New York City.

The event at the Metropolitan Club will feature one-on-one meetings with IMDX’s CEO Josh Riggs and CFO Andrea James. Interested investors are asked to contact their Lake Street sales representative to arrange meetings.

Market Reaction – IMDX

+4.17% $4.00

15m delay

+4.17% Vs previous close

$4.00 Last Price

$3.71 $4.02 Day Range

$130.90M Market Cap

0.7x Rel. Volume

Following this news, IMDX has gained 4.17%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $4.00.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The August 4 earnings-date notice was followed by a 1.79% move in IMDX, adding a recent scheduling-e...

Analysis

The August 4 earnings-date notice was followed by a 1.79% move in IMDX, adding a recent scheduling-event benchmark. This conference announcement offers access rather than new operating data; investors can watch subsequent disclosures, while low short positioning remains a volatility-risk context.

Key Figures

Conference date: September 10, 2026 Conference edition: 10th annual

2 metrics

Conference date September 10, 2026 Upcoming BIG10 Conference

Conference edition 10th annual Lake Street Capital Markets BIG10 Conference

Historical Context

5 past events · Latest: Aug 11 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	KOL event announcement	Neutral	+1.4%	Company scheduled a virtual discussion of GraftAssure and transplant rejection testing.
Aug 10	2Q26 earnings report	Negative	-7.1%	Quarterly results showed limited revenue, a net loss, and ongoing FDA review.
Aug 04	Earnings date notice	Neutral	+1.8%	Company announced its second-quarter results release and upcoming investor meetings.
Jul 23	Clinical data update	Positive	-0.6%	GraftAssure guided treatment monitoring in a published kidney-transplant study.
Jul 16	Medicare coverage update	Positive	-2.3%	MolDX coverage expanded reimbursement for transplant surveillance testing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two recent positive clinical or reimbursement updates were followed by negative 24-hour reactions, while the earnings release also declined.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10^th Annual Best Ideas Growth “BIG10” Conference taking place September 10^th, 2026 in New York.

Event: Lake Street Capital Markets 10^th Annual Best Ideas Growth “BIG10” Conference
Who: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James
Date: Thursday, September 10, 2026
Location: Metropolitan Club, New York City
Format: One-on-one meetings

Investors wishing to meet with IMDX management are encouraged to reach out to their Lake Street sales representative.

About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com 

FAQ

What conference will Insight Molecular Diagnostics (IMDX) attend in September 2026?

Insight Molecular Diagnostics (IMDX) will attend the Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference, scheduled for September 10, 2026, at the Metropolitan Club in New York City.

When and where is the Lake Street BIG10 conference featuring IMDX management?

The Lake Street 10th Annual Best Ideas Growth “BIG10” Conference featuring IMDX takes place on Thursday, September 10, 2026, at the Metropolitan Club, New York City.

Which Insight Molecular Diagnostics (IMDX) executives will attend the Lake Street BIG10 conference?

Insight Molecular Diagnostics will be represented by Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James at the Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference.

How can investors schedule a meeting with IMDX at the Lake Street BIG10 conference?

To schedule a one-on-one meeting with IMDX management at the conference, investors are encouraged to contact their Lake Street sales representative for arrangements.

What is the meeting format for IMDX at the Lake Street BIG10 conference?

Insight Molecular Diagnostics will participate in a one-on-one meetings format with investors during the Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference in New York City.